miércoles, septiembre 28, 2022
InicioNatureAndrogen receptor exercise in T cells limits checkpoint blockade efficacy

Androgen receptor exercise in T cells limits checkpoint blockade efficacy

[ad_1]

  • Beer, T. M. et al. Randomized, double-blind, section III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic sufferers with metastatic chemotherapy-naive castration-resistant prostate most cancers. J. Clin. Oncol. 35, 40–47 (2017).

    CAS 
    PubMed 

    Google Scholar
     

  • Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in sufferers with metastatic castration-resistant prostate most cancers that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, section 3 trial. Lancet Oncol. 15, 700–712 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fong, P. C. et al. Pembrolizumab plus enzalutamide in abiraterone-pretreated sufferers with metastatic castrate resistant prostate most cancers: cohort C of the section 1b/2 KEYNOTE-365 research. J. Clin. Oncol. 37, suppl:abstr 5010 (2019)

  • Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate most cancers: preliminary evaluation of sufferers within the CheckMate 650 trial. Most cancers Cell. 38, 489–499 (2020).

  • Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate most cancers: multicohort, open-label section II KEYNOTE-199 research. J. Clin. Oncol. 38, 395–405 (2020).

    CAS 
    PubMed 

    Google Scholar
     

  • Conforti, F. et al. Most cancers immunotherapy efficacy and sufferers’ intercourse: a scientific evaluate and meta-analysis. Lancet Oncol. 19, 737–746 (2018).

    CAS 
    PubMed 

    Google Scholar
     

  • Small, E. J. et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in sufferers with hormone-refractory prostate most cancers. Clin. Most cancers Res. 13, 1810–1815 (2007).

    CAS 
    PubMed 

    Google Scholar
     

  • Kissick, H. T. et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc. Natl Acad. Sci. USA 111, 9887–9892 (2014).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Benten, W. P. et al. Purposeful testosterone receptors in plasma membranes of T cells. FASEB J. 13, 123–133 (1999).

    CAS 
    PubMed 

    Google Scholar
     

  • Liva, S. M. & Voskuhl, R. R. Testosterone acts immediately on CD4+ T lymphocytes to extend IL-10 manufacturing. J. Immunol. 167, 2060–2067 (2001).

    CAS 
    PubMed 

    Google Scholar
     

  • Walecki, M. et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol. Biol. Cell 26, 2845–2857 (2015).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ayers, M. et al. IFN-gamma-related mRNA profile predicts medical response to PD-1 blockade. J. Clin. Make investments. 127, 2930–2940 (2017).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Most cancers Res. 77, 3540–3550 (2017).

    CAS 
    PubMed 

    Google Scholar
     

  • Riaz, N. et al. Tumor and microenvironment evolution throughout immunotherapy with nivolumab. Cell 171, 934–949.e916 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Graff, J. N. et al. Early proof of anti-PD-1 exercise in enzalutamide-resistant prostate most cancers. Oncotarget 7, 52810–52817 (2016).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Graff, J. N. et al. A section II single-arm research of pembrolizumab with enzalutamide in males with metastatic castration-resistant prostate most cancers progressing on enzalutamide alone. J. Immunother. Most cancers. 8, e000642 (2020).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Chen, P. L. et al. Evaluation of immune signatures in longitudinal tumor samples yields perception into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Most cancers Discov. 6, 827–837 (2016).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion throughout continual viral an infection. Immunity 27, 670–684 (2007).

    CAS 
    PubMed 

    Google Scholar
     

  • Hwang, S. S. et al. mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science 367, 1255–1260 (2020).

    CAS 
    PubMed 
    ADS 

    Google Scholar
     

  • Lefebvre, C. et al. A human B-cell interactome identifies MYB and FOXM1 as grasp regulators of proliferation in germinal facilities. Mol. Syst. Biol. 6, 377 (2010).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Alvarez, M. J. et al. Purposeful characterization of somatic mutations in most cancers utilizing network-based inference of protein exercise. Nat. Genet. 48, 838–847 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen, J. et al. NR4A transcription components restrict CAR T cell operate in stable tumours. Nature 567, 530–534 (2019).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Lu, X. et al. Efficient combinatorial immunotherapy for castration-resistant prostate most cancers. Nature 543, 728–732 (2017).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Northrop, J. Ok., Thomas, R. M., Wells, A. D. & Shen, H. Epigenetic transforming of the IL-2 and IFN-γ loci in reminiscence CD8 T cells is influenced by CD4 T cells. J. Immunol. 177, 1062–1069 (2006).

    CAS 
    PubMed 

    Google Scholar
     

  • Zediak, V. P., Johnnidis, J. B., Wherry, E. J. & Berger, S. L. Leading edge: persistently open chromatin at effector gene loci in resting reminiscence CD8+ T cells impartial of transcriptional standing. J. Immunol. 186, 2705–2709 (2011).

    CAS 
    PubMed 

    Google Scholar
     

  • Kersh, E. N. et al. Speedy demethylation of the IFN-γ gene happens in reminiscence however not naive CD8 T cells. J. Immunol. 176, 4083–4093 (2006).

    CAS 
    PubMed 

    Google Scholar
     

  • Pauken, Ok. E. et al. Epigenetic stability of exhausted T cells limits sturdiness of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Fornes, O. et al. JASPAR 2020: replace of the open-access database of transcription issue binding profiles. Nucleic Acids Res. 48, D87–D92 (2020).

    CAS 
    PubMed 

    Google Scholar
     

  • Nussing, S. et al. Environment friendly CRISPR/Cas9 gene modifying in uncultured naive mouse T cells for in vivo research. J. Immunol. 204, 2308–2315 (2020).

    CAS 
    PubMed 

    Google Scholar
     

  • Wherry, E. J., Blattman, J. N., Murali-Krishna, Ok., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and leads to distinct phases of useful impairment. J. Virol. 77, 4911–4927 (2003).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M. & Oldstone, M. B. Number of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently contaminated mice. Function in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160, 521–540 (1984).

    CAS 
    PubMed 

    Google Scholar
     

  • Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate most cancers. Cell 174, 758–769.e759 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).

    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Hugo, W. et al. Genomic and transcriptomic options of response to anti-PD-1 remedy in metastatic melanoma. Cell 168, 542 (2016).


    Google Scholar
     

  • Bebo, B. F., Schuster, J. C., Vandenbark, A. A. & Offner, H. Androgens alter the cytokine profile and scale back encephalitogenicity of myelin-reactive T cells. J. Immunol. 162, 35–40 (1999).

    CAS 
    PubMed 

    Google Scholar
     

  • Gubbels Bupp, M. R., Potluri, T., Fink, A. L. & Klein, S. L. The confluence of intercourse hormones and getting older on immunity. Entrance. Immunol. 9, 1269 (2018).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lin, A. A., Wojciechowski, S. E. & Hildeman, D. A. Androgens suppress antigen-specific T cell responses and IFN-γ manufacturing throughout intracranial LCMV an infection. J. Neuroimmunol. 226, 8–19 (2010).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ashley, D. J. The 2 “hit” and a number of “hit” theories of carcinogenesis. Br. J. Most cancers 23, 313–328 (1969).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cartwright, R. A., Gurney, Ok. A. & Moorman, A. V. Intercourse ratios and the dangers of haematological malignancies. Br. J. Haematol. 118, 1071–1077 (2002).

    PubMed 

    Google Scholar
     

  • Fish, E. N. The X-files in immunity: sex-based variations predispose immune responses. Nat. Rev. Immunol. 8, 737–744 (2008).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Prepare dinner, M. B., Chow, W. H. & Devesa, S. S. Oesophageal most cancers incidence in the US by race, intercourse, and histologic sort, 1977–2005. Br. J. Most cancers 101, 855–859 (2009).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Edgren, G., Liang, L., Adami, H. O. & Chang, E. T. Enigmatic intercourse disparities in most cancers incidence. Eur. J. Epidemiol. 27, 187–196 (2012).

    PubMed 

    Google Scholar
     

  • Klein, S. L. & Flanagan, Ok. L. Intercourse variations in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Montgomery, R. B. et al. Upkeep of intratumoral androgens in metastatic prostate most cancers: a mechanism for castration-resistant tumor progress. Most cancers Res. 68, 4447–4454 (2008).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pernigoni, N. et al. Commensal micro organism promote endocrine resistance in prostate most cancers by means of androgen biosynthesis. Science 374, 216–224 (2021).

    CAS 
    PubMed 
    ADS 

    Google Scholar
     

  • Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T. & Chakraborty, R. Genetic variation at 5 trimeric and tetrameric tandem repeat loci in 4 human inhabitants teams. Genomics 12, 241–253 (1992).

    CAS 
    PubMed 

    Google Scholar
     

  • Kazemi-Esfarjani, P., Trifiro, M. A. & Pinsky, L. Proof for a repressive operate of the lengthy polyglutamine tract within the human androgen receptor: attainable pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 4, 523–527 (1995).

    CAS 
    PubMed 

    Google Scholar
     

  • Rayford, W. et al. Comparative evaluation of 1152 African-American and European-American males with prostate most cancers identifies distinct genomic and immunological variations. Commun. Biol. 4, 670 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higano, C. S. et al. Actual-world outcomes of sipuleucel-T remedy in PROCEED, a potential registry of males with metastatic castration-resistant prostate. most cancers. Most cancers 125, 4172–4180 (2019).

    CAS 
    PubMed 

    Google Scholar
     

  • He, M. X. et al. Transcriptional mediators of remedy resistance in deadly prostate most cancers. Nat. Med. 27, 426–433 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bishop, J. L. et al. PD-L1 is very expressed in Enzalutamide resistant prostate most cancers. Oncotarget 6, 234–242 (2015).

    PubMed 

    Google Scholar
     

  • Aggarwal, R. et al. Scientific and genomic characterization of treatment-emergent small-cell neuroendocrine prostate most cancers: a multi-institutional potential research. J. Clin. Oncol. 36, 2492–2503 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Moran, A. E., Polesso, F. & Weinberg, A. D. Immunotherapy expands and maintains the operate of high-affinity tumor-infiltrating CD8 T cells in situ. J. Immunol. 197, 2509–2521 (2016).

    CAS 
    PubMed 

    Google Scholar
     

  • Polesso, F., Sarker, M., Weinberg, A. D., Murray, S. E. & Moran, A. E. OX40 agonist tumor immunotherapy doesn’t influence regulatory T cell suppressive operate. J. Immunol. 203, 2011–2019 (2019).

    CAS 
    PubMed 

    Google Scholar
     

  • Polesso, F., Weinberg, A. D. & Moran, A. E. Late-stage tumor regression after PD-L1 blockade plus a concurrent OX40 agonist. Most cancers Immunol. Res. 7, 269–281 (2019).

    CAS 
    PubMed 

    Google Scholar
     

  • Schofield, D. J. et al. Exercise of murine surrogate antibodies for durvalumab and tremelimumab missing effector operate and the flexibility to deplete regulatory T cells in mouse fashions of most cancers. mAbs 13, 1857100 (2021).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Polesso, F. et al. PD-1-specific “blocking” antibodies that deplete PD-1+ T cells current an inconvenient variable in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481 (2021).

    CAS 
    PubMed 

    Google Scholar
     

  • Valkenburg, Ok. C., Amend, S. R. & Pienta, Ok. J. Murine prostate micro-dissection and surgical castration. J. Vis. Exp. https://doi.org/10.3791/53984 (2016).

  • Pavese, J., Ogden, I. M. & Bergan, R. C. An orthotopic murine mannequin of human prostate most cancers metastasis. J. Vis. Exp. https://doi.org/10.3791/50873 (2013).

  • Moran, A. E. et al. T cell receptor sign energy in Treg and iNKT cell growth demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279–1289 (2011).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Murray, S. E. et al. Fibroblast-adapted human CMV vaccines elicit predominantly typical CD8 T cell responses in people. J. Exp. Med. 214, 1889–1899 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gruner, B. M. et al. An in vivo multiplexed small-molecule screening platform. Nat. Strategies 13, 883–889 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression information. Nat. Biotechnol. 33, 495–502 (2015).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu, D. & Smyth, G. Ok. Digicam: a aggressive gene set check accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Robertson, A. G. et al. Integrative evaluation identifies 4 molecular and medical subsets in uveal melanoma. Most cancers Cell 32, 204–220.e215 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Subramanian, A. et al. Gene set enrichment evaluation: a knowledge-based strategy for deciphering genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    CAS 
    PubMed 
    PubMed Central 
    ADS 

    Google Scholar
     

  • Li, B. & Dewey, C. N. RSEM: correct transcript quantification from RNA-seq information with or with out a reference genome. BMC Bioinf. 12, 323 (2011).

    CAS 

    Google Scholar
     

  • Ellrott, Ok. et al. Scalable open science strategy for mutation calling of tumor exomes utilizing a number of genomic pipelines. Cell Syst. 6, 271–281.e277 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • [ad_2]

    RELATED ARTICLES

    DEJA UNA RESPUESTA

    Por favor ingrese su comentario!
    Por favor ingrese su nombre aquí